Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-operative versus post-operative sublingual misoprostol with oxytocin during caesarean section in women at risk of primary postpartum haemorrhage
PACTR202503660614467Not yet recruiting
- Sponsor
- Ebolum Daniel Eziafa
- Start
- Mar 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Randomised, triple-blind trial of misoprostol and oxytocin in postpartum hemorrhage (PPH) (2 arms), sponsored by Ebolum Daniel Eziafa. Primary endpoints: Estimated intra-operative blood loss, Peri-operative fall in packed cell volume and 1 more. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
misoprostoloxytocin
03
Conditions
postpartum hemorrhage (PPH)
Beyond the preview
Go deeper on PACTR202503660614467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202503660614467.